BGB-A317-LBL-007-202: A Phase 2, Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of LBL-007 (Anti-Lag-3) in Combination with Tislelizumab (TIS; Anti-Pd-1) Plus Chemotherapy (chemo) As First-Line (1L) Treatment in Patients with Unresectable Locally Advanced/metastatic Esophageal Squamous Cell Carcinoma (ESCC)